Factors associated with buprenorphine versus methadone use in pregnancy

Substance Abuse

Volumn 37, Issue 4, 2016, Pages 550-557

  Krans, Elizabeth E ^a,b   Bogen, Debra ^a   Richardson, Gale ^a   Park, Seo Young ^a   Dunn, Shannon L ^b   Day, Nancy ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Buprenorphine; methadone; opioid use disorder; pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; COMPARATIVE STUDY; FEMALE; HUMAN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; YOUNG ADULT;

ACADEMIC MEDICAL CENTERS; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84983249433     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2016.1146649     Document Type: Article

References (39)

1. S.W.Patrick, R.E.Schumacher, B.D.Benneyworth, E.E.Krans, J.M.McAllister, M.M.Davis. Neonatal abstinence syndrome and associated health care expenditures:United States, 2000–2009. JAMA. 2012;307:1934–1940.
2. C.V.Almario, N.S.Seligman, K.C.Dysart, V.Berghella, J.K.Baxter. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009;201:326.e321–326.e326.
3. B.J.Cleary, J.M.Donnelly, J.D.Strawbridge, et al. Methadone and perinatal outcomes:a retrospective cohort study. Am J Obstet Gynecol. 2011;204:139.e131–139.e139.
4. L.P.Finnegan, J.F.ConnaughtonJr, R.E.Kron, J.P.Emich. Neonatal abstinence syndrome:assessment and management. Addictive diseases. 1975;2:141–158.
5. B.A.Logan, M.S.Brown, M.J.Hayes. Neonatal abstinence syndrome:treatment and pediatric outcomes. Clin Obstet Gynecol. 2013;56:186–192.
6. C.Dryden, D.Young, M.Hepburn, H.Mactier. Maternal methadone use in pregnancy:factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116:665–671.
7. J.D.Madden, J.N.Chappel, F.Zuspan, J.Gumpel, A.Mejia, R.Davis. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977;127:199–201.
8. L.Burns, E.Conroy, R.P.Mattick. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010;29:551–556.
9. E.S.Bandstra, C.E.Morrow, E.Mansoor, V.H.Accornero. Prenatal drug exposure:infant and toddler outcomes. J Addict Dis. 2010;29:245–258.
10. A.A.Creanga, J.C.Sabel, J.Y.Ko, et al. Maternal drug use and its effect on neonates:a population-based study in Washington State. Obstet Gynecol. 2012;119:924–933.
11. J.S.Dashe, G.L.Jackson, D.A.Olscher, E.H.Zane, G.D.WendelJr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92:854–858.
12. R.D.Stewart, D.B.Nelson, E.H.Adhikari, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013;209:267 e261–265.
13. H.Jones, L.Finnegan, K.Kaltenbach. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72:747–757.
14. H.E.Jones, K.Deppen, M.L.Hudak, et al. Clinical care for opioid-using pregnant and postpartum women:the role of obstetric providers. Am J Obstet Gynecol. 2014; 210:302–10.
15. National Institutes of Health, US Department of Health and Human Services. Effective Medical Treatment of Opiate Addiction. Effective Medical Treatment of Opiate Addiction. NIH Consens Statement 1997 Nov 17–19; 15(6):1–38.
16. V.Metz, R.Jagsch, N.Ebner, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol Clin Exp. 2011;26:412–421.
17. J.Kakko, M.Heilig, I.Sarman. Buprenorphine and methadone treatment of opiate dependence during pregnancy:comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69–78.
18. G.Fischer, R.Ortner, K.Rohrmeister, et al. Methadone versus buprenorphine in pregnant addicts:a double-blind, double-dummy comparison study. Addiction. 2006;101:275–281.
19. I.Lacroix, A.Berrebi, D.Garipuy, et al. Buprenorphine versus methadone in pregnant opioid-dependent women:a prospective multicenter study. Eur J Clin Pharmacol. 2011;67:1053–1059.
20. H.E.Jones, K.Kaltenbach, S.H.Heil, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–2331.
21. B.A.Moore, D.A.Fiellin, D.T.Barry, et al. Primary care office-based buprenorphine treatment:comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22:527–530.
22. D.A.Fiellin, R.S.Schottenfeld, C.J.Cutter, B.A.Moore, D.T.Barry, P.G.O'Connor. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence:a randomized clinical trial. JAMA Intern Med. 2014;174:1947–1954.
23. E.S.Jones, B.A.Moore, J.L.Sindelar, P.G.O'Connor, R.S.Schottenfeld, D.A.Fiellin. Cost analysis of clinic and office-based treatment of opioid dependence:results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99:132–140.
24. D.A.Fiellin, H.Kleber, J.G.Trumble-Hejduk, A.T.McLellan, T.R.Kosten. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27:153–159.
25. D.T.Barry, K.S.Irwin, E.S.Jones, et al. Integrating buprenorphine treatment into office-based practice:a qualitative study. J Gen Intern Med. 2009;24:218–225.
26. C.Teruya, R.P.Schwartz, S.G.Mitchell, et al. Patient perspectives on buprenorphine/naloxone:a qualitative study of retention during the Starting Treatment With Agonist Replacement Therapies (START) study. J Psychoactive Drugs. 2014;46:412–426.
27. J.S.Potter, E.N.Marino, M.P.Hillhouse, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users:findings from Starting Treatment With Agonist Replacement Therapies (START). J Stud Alcohol Drugs. 2013;74:605–613.
28. R.P.Mattick, J.Kimber, C.Breen, M.Davoli. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
29. G.Fischer, W.Gombas, H.Eder, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999;94:1337–1347.
30. F.E.Harrell. Regression Modeling Strategies:With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York:Springer; 2001.
31. G.E.P.Box, N.R.Draper. Empirical Model-Building and Response Surfaces. New York:John Wiley & Sons; 1987.
32. E.W.Steyerberg. Clinical Prediction Models. New York:Springer; 2009.
33. H.Hansen, C.Siegel, B.Case, D.Bertollo, D.DiRocco, M.Galanter. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40:367–377.
34. E.S.Jones, D.A.Fiellin. Women and opioid dependence treatment:office-based versus opioid treatment program-based care? Subst Abus. 2007;28:3–8.
35. R.P.Mattick, C.Breen, J.Kimber, M.Davoli. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
36. S.D.Whitley, N.L.Sohler, H.V.Kunins, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39:51–57.
37. H.E.Jones, S.H.Heil, A.Baewert, et al. Buprenorphine treatment of opioid-dependent pregnant women:a comprehensive review. Addiction. 2012;107(Suppl 1):5–27.
38. T.J.Cicero, M.S.Ellis, H.L.Surratt, S.P.Kurtz. The changing face of heroin use in the United States:a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71:821–826.
39. M.Terplan, E.J.Smith, S.H.Glavin. Trends in injection drug use among pregnant women admitted into drug treatment:1994–2006. J Womens Health. 2010;19:499–505.